Before revision: One exon-skipping drug was approved in 2016 by the US FDA: eteplirsen (ExonDys51), a Morpholino oligo from Sarepta Therapeutics targeting exon 51 of human dystrophin.
After revision: ,One exon-skipping drug was approved in 2016 by the US FDA: eteplirsen (ExonDys51), a Morpholino oligo from Sarepta Therapeutics targeting exon 51 of human dystrophin.